Updates on CAR T-Cell Therapy in Myeloma
Published on June 14, 2018
The emergence of the impressive, high-tech CAR T-cell therapy, using your own genetically modified T cells to combat cancer, has generated a lot of buzz throughout the cancer community. Although it is still being evaluated in clinical trials for certain types of cancers, many multiple myeloma patients wonder if it could work for them. Where is research today on CAR T-cell therapy for myeloma? What role will this immunotherapy play in myeloma care? On location at the 2018 American Society of Clinical Oncology (ASCO) meeting in Chicago, Dr. James Berenson gives an expert perspective on the efficacy, value, toxicity and cost of CAR T-cell therapy for myeloma. Watch now to find out the latest treatment developments.
Featuring
You might also like
Transcript | Updates on CAR T-Cell Therapy in Myeloma
Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.
Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.
Andrew Schorr:
Many people are starting to hear about CAR-T, chimeric antigen receptor T-cell therapy for myeloma.
Dr. Berenson:
Right.
Andrew Schorr:
Experimental, some of us who cover myeloma know a woman named Cherie Rineker in Houston who had one recently. She was near death, and a couple of days ago, folks, she was gardening. What's your view about CAR-T? It's experimental, doesn't work for everybody. Does that have a place notwithstanding how you feel about transplant?
Dr. Berenson:
Let's go different because we're not just generally throwing a bunch of chemo, but the general bone marrow we're trying to target against specifically the myeloma cell. I think it's a work in progress. It's certainly active. Now, where it's going to fit in I'm not sure yet. We're going to have to tamp down the toxicity, and we're certainly going to have to look at the cost of this newer modality treatment of myeloma.
There are a number of ways it's being done. A lot of people are targeting BCMA. Others are targeting other protein, and, you know, there's a lot of work to be done on this in order to make it user friendly. Right now it's pretty cumbersome. It's really being done at major medical centers only, and there's certainly some side effects, something called cytokine release syndrome, which can be really daunting for these health staff, the nurses and ancillary healthcare professionals to take care of.
Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.
